Neuromuscular blockade reversal with sugammadex versus pyridostigmine/ glycopyrrolate in laparoscopic cholecystectomy: a randomized trial of effects on postoperative gastrointestinal motility

다국어 초록 (Multilingual Abstract)

Background: Acetylcholinesterase inhibitors (e.g., pyridostigmine bromide) are used for neuromuscular blockade (NMB) reversal in patients undergoing surgery under general anesthesia (GA). Concurrent use of anticholinergic agents (e.g., glycopyrrolate) decreases cholinergic side effects but can impede bowel movements. Sugammadex has no cholinergic effects; its use modifies recovery of gastrointestinal (GI) motility following laparoscopic cholecystectomy compared to pyridostigmine/glycopyrrolate. This study evaluated the contribution of sugammadex to the recovery of GI motility compared with pyridostigmine and glycopyrrolate.
Methods: We conducted a prospective study of patients who underwent laparoscopic cholecystectomy. Patients were randomly allocated to the experimental group (sugammadex, Group S) or control group (pyridostigmine-glycopyrrolate, Group P). After anesthesia (propofol and rocuronium, and 2% sevoflurane), recovery was induced by injection of sugammadex or a pyridostigmine-glycopyrrolate mixture. As a primary outcome, patients recorded the time of their first passage of flatus (‘gas-out time’) and defecation. The secondary outcome was stool types.
Results: One-hundred and two patients participated (Group S [n = 49], Group P [n = 53]). Mean time from injection of NMB reversal agents to gas-out time was 15.03 (6.36–20.25) h in Group S and 20.85 (16.34–25.86) h in Group P (P = 0.001). Inter-group differences were significant. Time until the first defecation as well as types of stools was not significantly different.
Conclusions: Sugammadex after laparoscopic cholecystectomy under GA resulted in an earlier first postoperative passage of flatus compared with the use of a mixture of pyridostigmine and glycopyrrolate. These findings suggest that the use of sugammadex has positive effects on the recovery of GI motility.

참고문헌 (Reference)

1 Chae YJ, "Thirty-day postoperative outcomes following sugammadex use in colorectal surgery patients; retrospective study" 8 : E97-, 2019

2 Althausen PL, "The use of neostigmine to treat postoperative ileus in orthopedic spinal patients" 14 : 541-545, 2001

3 Jones C, "The role of carbohydrate drinks in preoperative nutrition for elective colorectal surgery" 93 : 504-507, 2011

4 De Giorgio R, "The pharmacological treatment of acute colonic pseudo-obstruction" 15 : 1717-1727, 2001

5 Olesnicky BL, "The effect of routine availability of sugammadex on postoperative respiratory complications : a historical cohort study" 83 : 248-254, 2017

6 Thomas Fuchs-Buder, "Sugammadex: clinical development and practical use" 대한마취통증의학회 65 (65): 495-500, 2013

7 차정은, "Sugammadex use can decrease the incidence of post-operative urinary retention by avoiding anticholinergics: a retrospective study" 대한마취통증의학회 13 (13): 40-46, 2018

8 Sacan O, "Sugammadex reversal of rocuronium-induced neuromuscular blockade : a comparison with neostigmine-glycopyrrolate and edrophonium-atropine" 104 : 569-574, 2007

9 Sen A, "Reversal of neuromuscular blockade with sugammadex or neostigmine/atropine : effect on postoperative gastrointestinal motility" 32 : 208-213, 2016

10 Livingston EH, "Postoperative ileus" 35 : 121-132, 1990

11 Blobner M, "Neuromuscular blockade improves surgical conditions(NISCO)" 29 : 627-636, 2015

12 Kreis ME, "Neostigmine increases postoperative colonic motility in patients undergoing colorectal surgery" 130 : 449-456, 2001

13 Butterworth JF, "Morgan & Mikhail’s Clinical Anesthesiology" McGraw-Hill 235-236, 2013

14 Butterworth JF, "Morgan & Mikhail’s Clinical Anesthesiology" McGraw-Hill 1166-1169, 2013

15 Murphy GS, "Miller’s Anesthesia" Churchill Livinstone, Elsevier Health Sciences 995-1025, 2014

16 Khosla S, "Harrison’s Principles of Internal Medicine" McGraw-Hill 959-, 2009

17 Gustafsson UO, "Guidelines for perioperative care in elective colonic surgery : enhanced recovery after surgery(ERAS®)society recommendations" 37 : 259-284, 2013

18 Mirakhur RK, "Glycopyrrolate : pharmacology and clinical use" 38 : 1195-1204, 1983

19 Annese V, "Gastrointestinal motility disorders in patients with inactive Crohn"s disease" 32 : 1107-1117, 1997

20 Ilce A, "Fecal Incontinence - Causes, Management and Outcome. Bristol Stool Chart" IntechOpen

21 Scott MJ, "Enhanced recovery after surgery(ERAS)for gastrointestinal surgery, part 1 : pathophysiological considerations" 59 : 1212-1231, 2015

22 Melnyk M, "Enhanced recovery after surgery (ERAS) protocols: time to change practice?" 5 : 342-348, 2011

23 Brueckmann B, "Effects of sugammadex on incidence of postoperative residual neuromuscular blockade : a randomized, controlled study" 115 : 743-751, 2015

24 Wilkins JL, "Effects of neostigmine and atropine on motor activity of ileum, colon, and rectum of anaesthetized subjects" 1 : 793-794, 1970

25 Hearing SD, "Effect of cholecystectomy on bowel function : a prospective, controlled study" 45 : 889-894, 1999

26 Sustic A, "Early postoperative gastric emptying in patients undergoing laparoscopic cholecystectomy: sugammadex vs. neostigmine/atropine neuromuscular blockade reversal agents: 9AP4-1" 29 : 140-, 2012

27 Cheng CR, "Does neostigmine administration produce a clinically important increase in postoperative nausea and vomiting?" 101 : 1349-1355, 2005

28 Feldman M, "Disorders of gastrointestinal motility associated with diabetes mellitus" 98 : 378-384, 1983

29 Lassen K, "Consensus review of optimal perioperative care in colorectal surgery : enhanced recovery after surgery(ERAS)group recommendations" 144 : 961-969, 2009

30 Mirakhur RK, "Comparison of atropine and glycopyrrolate in a mixture with pyridostigmine for the antagonism of neuromuscular block" 53 : 1315-1320, 1981